Success Metrics

Completion Rate
0%(0/2)
Active Trials
0(0%)
Terminated
2(50%)

Phase Distribution

Ph phase_2
1
25%
Ph phase_3
2
50%

Phase Distribution

0

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
2(66.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Terminated(2)
Other(2)

Detailed Status

Terminated2
unknown2

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 21 (33.3%)
Phase 32 (66.7%)

Trials by Status

terminated250%
unknown250%

Recent Activity

0 active trials
Showing 4 of 4
terminatedphase_3

A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis at Risk for Pulmonary Hypertension

NCT03267108
unknownphase_2

A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis

NCT05747508
terminatedphase_3

A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19

NCT04421508
unknown

Expanded Access for Patients With Pulmonary Hypertension Associated With Pulmonary Fibrosis

NCT05356052

Clinical Trials (4)

Showing 4 of 4 trials
NCT03267108Phase 3

A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis at Risk for Pulmonary Hypertension

Terminated
NCT05747508Phase 2

A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis

Unknown
NCT04421508Phase 3

A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19

Terminated
NCT05356052

Expanded Access for Patients With Pulmonary Hypertension Associated With Pulmonary Fibrosis

Unknown

All 4 trials loaded

Drug Details

Intervention Type
COMBINATION PRODUCT
Total Trials
4